Brainsway Ltd. Sponsored ADR BWAY
- Market cap
- $531.6M
- P/E
- 28.9×
Follow BWAY
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | 4.00 | 2.55 | 3.45 | 0.82 | 0.69 | 2.31 | 3.92 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | 6.20 | 6.27 | 5.88 | 4.59 | 3.68 | 5.49 | 9.90 |
High Price
|
|||
| — | — | 96 | 107 | 100 | 118 | 134 | 106 | 120 | 129 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 11 | 11 | 16 | 23 | 22 | 30 | 27 | 32 | 41 | 52 |
Revenue
|
|||
| 77.27% | 75.16% | 78.11% | 77.80% | 77.07% | 77.75% | 73.77% | 73.86% | 74.56% | 75.42% |
Gross Margin
|
|||
| (2) | (7) | (6) | (10) | (5) | (6) | (13) | (4) | 3 | 8 |
EBT
|
|||
| (21.69%) | (64.53%) | (38.24%) | (42.88%) | (23.34%) | (21.64%) | (47.96%) | (12.41%) | 8.43% | 14.76% |
EBT Margin
|
|||
| (2) | 0 | (6) | (10) | (5) | (6) | (13) | (4) | 3 | 8 |
Net Income
|
|||
| 1 | 1 | 1 | 3 | 2 | 2 | 2 | 1 | 2 | 2 |
Depreciation
|
|||
| 1.52 | 1.41 | 0.99 | 1.13 | 0.98 | 0.95 | 0.82 | 0.96 | 2.41 | 2.75 |
Revenue/Sh
|
|||
| (0.17) | (0.50) | (0.39) | (0.50) | (0.24) | (0.21) | (0.40) | (0.13) | 0.17 | 0.40 |
Earnings/Sh
|
|||
| (0.33) | (0.46) | (0.23) | (0.35) | (0.06) | 0.03 | (0.30) | 0.04 | 0.61 | 0.92 |
Cash Flow/Sh
|
|||
| 0.00 | 0.00 | (0.12) | (0.16) | (0.11) | (0.07) | 0.06 | (0.07) | (0.22) | (0.12) |
Capex/Sh
|
|||
| (0.33) | (0.46) | (0.35) | (0.51) | (0.17) | (0.04) | (0.24) | (0.03) | 0.38 | 0.80 |
Free CF/Sh
|
|||
| 1.42 | 1.62 | 0.42 | 1.18 | 0.87 | 1.84 | 1.38 | 1.25 | 3.67 | 3.85 |
Book Value/Sh
|
|||
| 7 | 8 | 17 | 21 | 22 | 31 | 33 | 33 | 17 | 19 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 55.53 | 26.42 |
PE Ratio
|
|||
| 5.35 | 5.35 | 5.35 | 4.33 | 3.84 | 4.04 | 1.38 | 3.77 | 1.95 | 3.46 |
PS Ratio
|
|||
| 17.80 | 17.80 | 17.80 | 4.13 | 4.31 | 2.09 | 0.83 | 2.88 | 1.29 | 2.47 |
PB Ratio
|
|||
| 5.08 | 5.08 | 5.08 | 3.48 | 3.16 | 2.14 | (0.36) | 2.47 | 0.38 | 2.23 |
EV/Sales
|
|||
| (15.32) | (15.32) | (15.32) | (7.61) | (17.82) | (46.79) | 1.25 | (71.24) | 2.41 | 7.69 |
EV/FCF
|
|||
| (2) | (4) | (4) | (7) | (1) | 1 | (10) | 1 | 10 | 17 |
Op' Cash Flow
|
|||
| 0 | (1) | (2) | (3) | (2) | (2) | 2 | (2) | (4) | (2) |
Capex
|
|||
| (2) | (4) | (6) | (11) | (4) | (1) | (8) | (1) | 7 | 15 |
FCF
|
|||
| 9 | 12 | 5 | 22 | 17 | 56 | 50 | 46 | 64 | 61 |
Working Cap'
|
|||
| — | 3 | 3 | 0 | 1 | 1 | 0 | — | — | — |
Total Debt
|
|||
| (10) | (12) | (6) | (21) | (17) | (57) | (47) | (46) | (70) | (69) |
Net Debt
|
|||
| 10 | 13 | 7 | 24 | 20 | 57 | 45 | 42 | 62 | 73 |
Sh' Equity
|
|||
| (10.19%) | (73.09%) | (54.90%) | (33.14%) | (14.80%) | (11.78%) | (19.04%) | (6.59%) | 3.71% | 7.30% |
ROA
|
|||
| 0.00% | 0.00% | (446.40%) | (193.46%) | (96.61%) | (426.23%) | 0.00% | 0.00% | 0.00% | 71.48% |
ROIC
|
|||
| (20.80%) | (63.48%) | (65.85%) | (66.26%) | (24.56%) | (16.79%) | (25.99%) | (9.65%) | 5.62% | 11.18% |
ROE
|
|||
Brainsway Ltd. Sponsored ADR peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CERS Cerus Corporation | $524.0M | 0.0× | Compare |
| TCMD Tactile Systems Technology, Inc. | $518.5M | 20.7× | Compare |
| SENS Senseonics Holdings, Inc. | $546.7M | 0.0× | Compare |
| DCTH Delcath Systems, Inc. | $558.0M | 1,560× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| MASS 908 Devices Inc. | $492.7M | 0.0× | Compare |
| PACB Pacific Biosciences of California, Inc. | $484.9M | 0.0× | Compare |
| NPCE NeuroPace, Inc. | $479.5M | 0.0× | Compare |
| SGHT Sight Sciences, Inc. | $478.2M | 0.0× | Compare |
Brainsway Ltd. Sponsored ADR (BWAY) key facts
- Brainsway Ltd. Sponsored ADR (BWAY) is a Medical Devices company in the Healthcare sector, traded in the US as an ADR.
- Brainsway Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was ILS 52.2 million, up 27.3% from fiscal 2024.
- As of September 25, 2026, BWAY traded at $13.31, a market capitalization of $531.6 million.
- Return on equity was 11.2% and debt-to-equity 0.00.
Brainsway Ltd. Sponsored ADR (BWAY) Latest News
10 Sep
BrainsWay’s (BWAY) growth streak continues and becomes increasingly prominent, drawing greater attention to the company’s performance and trajectory. Sustained growth momentum points to stronger future revenue and investor interest for BWAY.
8 Sep
BrainsWay reports promising pilot study results for Deep TMS treatment in patients with depression and comorbid early-stage Alzheimer’s disease. Pilot study results point to potential new treatment applications that may support moderate long-term market growth.
27 Aug
BrainsWay Deep TMS study shows 70% reduction in patients experiencing suicidal ideation. Positive Deep TMS efficacy data directly supports expanded adoption and revenue potential for core product.
17 Aug
Brainsway (BWAY) upgraded to Buy rating. Buy upgrade can lift near-term investor sentiment and share price.
13 Aug
Brainsway Ltd. discussed Q2 financial results and operational updates in its earnings call, covering revenue performance, adoption of deep TMS systems, and growth initiatives in mental health treatment markets. Q2 earnings details provide financial and strategic updates that may moderately influence near-term stock sentiment and operational outlook.
12 Aug
BrainsWay Ltd reported 35% revenue growth to $17 million in Q2 2026. 35% revenue surge reflects major positive shift in financial results and investor outlook.
BrainsWay Ltd. Sponsored ADR (BWAY) released second quarter 2026 financial results and operational highlights. Quarterly financial results can moderately affect valuation and near-term market sentiment.
24 Jul
Brainsway Ltd. Sponsored ADR (BWAY) is named Bull of the Day on positive outlook for its deep transcranial magnetic stimulation technology targeting brain disorders and expanding clinical applications. Bull of the Day designation can lift short-term sentiment and trading volume for BWAY but does not alter core fundamentals or long-term trajectory.
20 Jul
BrainsWay announces strategic investment in Radial Health, Inc. Strategic investment represents major move likely to significantly alter BrainsWay trajectory and investor sentiment.
29 Jun
BrainsWay presented positive data from the largest real-world study of Deep TMS in patients with comorbid PTSD and major depressive disorder. Positive real-world study data on Deep TMS for PTSD and depression supports expanded clinical use and strengthens company growth prospects.
22 Jun
BrainsWay reports favorable coverage for Accelerated Deep TMS expanding to over 57 million covered lives. Expanded reimbursement for BrainsWay's core Deep TMS therapy to over 57 million lives boosts treatment access and revenue potential.
9 Jun
BrainsWay presented first 12-month durability data for its SWIFT™ Accelerated Deep TMS at the Clinical TMS Society Annual Meeting. Positive durability data on core product may boost clinical adoption and near-term commercial traction.
13 May
BrainsWay Ltd (BRSYF) reported record revenue growth and detailed strategic initiatives in its Q1 2026 earnings call highlights. Record revenue growth and strategic initiatives indicate major positive shifts in financial performance and competitive positioning.
Brainsway released Q1 earnings call highlights detailing financial results, operational updates, and future outlook for the company. Q1 earnings highlights cover revenue, profitability, guidance, and strategic developments that significantly influence BWAY's trajectory and investor sentiment.
BrainsWay Ltd. (BWAY) released the full transcript of its Q1 2026 earnings conference call. Q1 2026 earnings call transcript details financial results, operational updates, and guidance that could significantly shape investor sentiment and stock trajectory.
BrainsWay reported first quarter 2026 financial results and operational highlights. Quarterly financial results and operational updates moderately affect financial performance and investor sentiment.
15 Apr
BrainsWay reports expanding U.S. payer support for transcranial magnetic stimulation (TMS) therapy administered by nurse practitioners, improving access and reimbursement for its Deep TMS system. Expanding payer support for nurse practitioner-administered TMS enhances treatment accessibility, reimbursement, and adoption of BrainsWay's core Deep TMS technology.
13 Apr
Brainsway (BWAY) upgraded to Strong Buy rating by analysts, highlighting positive developments in its Deep TMS technology, strong clinical trial results, expanding commercial footprint, and attractive valuation metrics. Analyst upgrade to Strong Buy signals major positive shift in investor sentiment and potential stock price surge.
2 Apr
Brainsway Ltd. Sponsored ADR (BWAY) is well poised for a stock surge due to favorable developments in its operations and market position. Favorable positioning for surge signals significant potential boost to BWAY's trajectory and investor sentiment.
30 Mar
Neurolief secures $6 million investment following FDA approval of Proliv™Rx, a brain neuromodulation therapy expanding access for patients with inadequate antidepressant response. FDA approval and $6M funding for Neurolief's neuromodulation device directly compete with Brainsway in depression treatment, shifting market dynamics.
26 Mar
Brainsway Ltd. Sponsored ADR (BWAY) exhibits strong momentum poised to continue, driven by positive technical indicators and fundamentals. Bullish momentum forecast signals major uplift in investor sentiment and stock trajectory.
BrainsWay completed an additional $6 million milestone-based investment in Neurolief Ltd. following FDA approval of the Proliv™Rx System for treating Major Depressive Disorder (MDD). The milestone investment post-FDA approval bolsters BrainsWay's strategic stake in innovative MDD neuromodulation technology.
19 Mar
BrainsWay Ltd. (BWAY) completed a revenue-based milestone investment into Axis Integrated Mental Health, advancing its strategic expansion in the mental health sector through tied future revenues. Revenue-based milestone investment into a mental health provider represents a major strategic move enhancing BrainsWay's growth and investor sentiment.
11 Mar
BrainsWay Ltd (BRSYF) Q4 2025 earnings call highlights record revenue growth and strategic advances. Record revenue growth and strategic advances indicate major positive shifts in financial performance and competitive positioning.
Brainsway Ltd. (BWAY) Q4 earnings call highlights financial results, operational progress, Deep TMS treatment expansions, revenue growth, and optimistic 2024 guidance amid strong demand. Q4 earnings highlights detail revenue beats, treatment volume surges, and positive guidance signaling major boosts to financial performance and investor confidence.
BrainsWay reported fourth quarter and full year 2025 financial results alongside operational highlights. Quarterly and annual financial results directly shape investor sentiment and company valuation trajectory.
4 Mar
Landmark data validate BrainsWay’s SWIFT™ Deep TMS, confirming its efficacy and ushering in a new era of depression treatment. Landmark validation of core SWIFT Deep TMS technology fundamentally redefines BrainsWay's competitive edge in depression treatment.
19 Feb
BrainsWay announces new minority-stake investment in Canadian provider BrainStim Health Inc. Minority stake in Canadian peer provider supports strategic expansion and market reach without fundamentally altering core operations.
18 Feb
Cigna’s Evernorth Behavioral Health will eliminate prior authorization requirements for BrainsWay's TMS coverage, accelerating patient access to care. Removal of prior authorizations by major insurer Cigna removes key barrier to TMS adoption, significantly boosting BrainsWay's treatment volumes and revenue potential.
11 Feb
Brainsway Ltd. Sponsored ADR (BWAY) is highlighted as a potential investment opportunity in the Middle East market for February 2026, focusing on undiscovered gems that may offer significant growth potential. The article emphasizes the strategic importance of exploring these markets for future expansion and profitability. Exploring new markets could moderately influence Brainsway's growth and competitive positioning.